Role of the integrin-linked kinase/TGF-β/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy.
Anfal F Bin DayelAsma S AlonaziNawal M AlrasheedMaha A AlaminWedad S SarawiAbeer O AlharbiNahla'a A AlabbadDanah A AlbuaijanDareen N AlassiriAlanoud F AljarbuaFatimah K AlmusaytirNouf M AlrasheedPublished in: The Journal of pharmacy and pharmacology (2023)
Sitagliptin could afford cardioprotective effects for the first time by altering ILK-associated TGF-β/SMAD signaling pathways. Thus, sitagliptin may be a promising therapeutic target for the prevention of diabetic cardiomyopathy.